{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T21:37:08Z","timestamp":1792791428507,"version":"4.5.0"},"reference-count":80,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,11,25]],"date-time":"2024-11-25T00:00:00Z","timestamp":1732492800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100017577","name":"CTI Biopharma","doi-asserted-by":"publisher","award":["CFE\/BI\/72-19"],"award-info":[{"award-number":["CFE\/BI\/72-19"]}],"id":[{"id":"10.13039\/100017577","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008782","name":"Spanish Society of Hemotology and Hemotherapy","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100008782","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100014440","name":"Spain Ministry of Science and Innovation","doi-asserted-by":"publisher","award":["FPU18\/03189"],"award-info":[{"award-number":["FPU18\/03189"]}],"id":[{"id":"10.13039\/100014440","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"Carlos III Health Institute","doi-asserted-by":"publisher","award":["PI18\/00316"],"award-info":[{"award-number":["PI18\/00316"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"Carlos III Health Institute","doi-asserted-by":"publisher","award":["PI21\/00347"],"award-info":[{"award-number":["PI21\/00347"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"Carlos III Health Institute","doi-asserted-by":"publisher","award":["PI23\/00027"],"award-info":[{"award-number":["PI23\/00027"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100031478","name":"NextGenerationEU","doi-asserted-by":"publisher","award":["PMP21\/00052"],"award-info":[{"award-number":["PMP21\/00052"]}],"id":[{"id":"10.13039\/100031478","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biomedicine &amp; Pharmacotherapy"],"published-print":{"date-parts":[[2024,12]]},"DOI":"10.1016\/j.biopha.2024.117712","type":"journal-article","created":{"date-parts":[[2024,11,26]],"date-time":"2024-11-26T18:59:49Z","timestamp":1732647589000},"page":"117712","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"C","title":["Pacritinib prevents inflammation-driven myelofibrosis-like phenotype in a miR-146a-\/- murine model"],"prefix":"10.1016","volume":"181","author":[{"given":"Ernesto Jos\u00e9","family":"Cuenca-Zamora","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Constantino","family":"Mart\u00ednez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda Luz","family":"Morales","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pedro Jes\u00fas","family":"Guijarro-Carrillo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda Jos\u00e9","family":"L\u00f3pez-Poveda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos","family":"Alcolea-Guardiola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalia","family":"Vidal-Garrido","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda Luisa","family":"Lozano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roc\u00edo","family":"Gonzalez-Conejero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6741-9725","authenticated-orcid":false,"given":"Ra\u00fal","family":"Teruel-Montoya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9520-3243","authenticated-orcid":false,"given":"Francisca","family":"Ferrer-Mar\u00edn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"11","key":"10.1016\/j.biopha.2024.117712_bib1","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1182\/blood.2022015850","article-title":"International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data","volume":"140","author":"Arber","year":"2022","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.biopha.2024.117712_bib2","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1038\/s41375-022-01613-1","article-title":"The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic\/Dendritic Neoplasms","volume":"36","author":"Khoury","year":"2022","journal-title":"Leukemia"},{"issue":"11","key":"10.1016\/j.biopha.2024.117712_bib3","doi-asserted-by":"crossref","DOI":"10.1038\/bcj.2015.95","article-title":"Blast transformation and fibrotic progression in polycythemia vera and essential thrombocythemia: a literature review of incidence and risk factors","volume":"5","author":"Cerquozzi","year":"2015","journal-title":"Blood Cancer J."},{"issue":"4","key":"10.1016\/j.biopha.2024.117712_bib4","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1016\/j.mayocp.2018.08.022","article-title":"3023 Mayo Clinic patients with myeloproliferative neoplasms: risk-stratified comparison of survival and outcomes data among disease subgroups","volume":"94","author":"Szuber","year":"2019","journal-title":"Mayo Clin. Proc."},{"issue":"5","key":"10.1016\/j.biopha.2024.117712_bib5","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1002\/ajh.26857","article-title":"Primary myelofibrosis: 2023 update on diagnosis, risk-stratification, and management","volume":"98","author":"Tefferi","year":"2023","journal-title":"Am. J. Hematol."},{"issue":"7","key":"10.1016\/j.biopha.2024.117712_bib6","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/j.clml.2024.03.001","article-title":"Triple-Negative Myelofibrosis: Disease Features, Response to Treatment and Outcomes","volume":"24","author":"Aguirre","year":"2024","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"issue":"24","key":"10.1016\/j.biopha.2024.117712_bib7","doi-asserted-by":"crossref","first-page":"3227","DOI":"10.1182\/blood-2017-01-761999","article-title":"Presentation and outcome of patients with 2016 WHO diagnosis of prefibrotic and overt primary myelofibrosis","volume":"129","author":"Guglielmelli","year":"2017","journal-title":"Blood"},{"issue":"16","key":"10.1016\/j.biopha.2024.117712_bib8","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1182\/blood.2022017578","article-title":"Genetic basis and molecular profiling in myeloproliferative neoplasms","volume":"141","author":"Luque Paz","year":"2023","journal-title":"Blood"},{"issue":"16","key":"10.1016\/j.biopha.2024.117712_bib9","doi-asserted-by":"crossref","first-page":"1922","DOI":"10.1182\/blood.2022017416","article-title":"Biology and therapeutic targeting of molecular mechanisms in MPNs","volume":"141","author":"How","year":"2023","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.biopha.2024.117712_bib10","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1038\/leu.2016.12","article-title":"Myeloproliferative neoplasms and inflammation: whether to target the malignant clone or the inflammatory process or both","volume":"30","author":"Koschmieder","year":"2016","journal-title":"Leukemia"},{"issue":"5","key":"10.1016\/j.biopha.2024.117712_bib11","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1182\/bloodadvances.2023011338","article-title":"IL-1\u03b2 promotes MPN disease initiation by favoring early clonal expansion of JAK2-mutant hematopoietic stem cells","volume":"8","author":"Rai","year":"2024","journal-title":"Blood Adv."},{"issue":"3","key":"10.1016\/j.biopha.2024.117712_bib12","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1158\/2159-8290.CD-14-0736","article-title":"JAK-STAT pathway activation in malignant and nonmalignant cells contributes to MPN pathogenesis and therapeutic response","volume":"5","author":"Kleppe","year":"2015","journal-title":"Cancer Discov."},{"issue":"1","key":"10.1016\/j.biopha.2024.117712_bib13","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.ccell.2017.11.009","article-title":"Dual Targeting of Oncogenic Activation and Inflammatory Signaling Increases Therapeutic Efficacy in Myeloproliferative Neoplasms","volume":"33","author":"Kleppe","year":"2018","journal-title":"Cancer Cell"},{"issue":"1","key":"10.1016\/j.biopha.2024.117712_bib14","doi-asserted-by":"crossref","first-page":"5347","DOI":"10.1038\/s41467-022-32928-3","article-title":"Interleukin-1 contributes to clonal expansion and progression of bone marrow fibrosis in JAK2V617F-induced myeloproliferative neoplasm","volume":"13","author":"Rahman","year":"2022","journal-title":"Nat. Commun."},{"issue":"18","key":"10.1016\/j.biopha.2024.117712_bib15","doi-asserted-by":"crossref","first-page":"2051","DOI":"10.1182\/blood.2019004095","article-title":"Increased CXCL4 expression in hematopoietic cells links inflammation and progression of bone marrow fibrosis in MPN","volume":"136","author":"Gleitz","year":"2020","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.biopha.2024.117712_bib16","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1158\/2643-3230.BCD-23-0210","article-title":"Trisomy 8 Defines a Distinct Subtype of Myeloproliferative Neoplasms Driven by the MYC\u2013Alarmin Axis","volume":"5","author":"Vincelette","year":"2024","journal-title":"Blood Cancer Discov."},{"issue":"1","key":"10.1016\/j.biopha.2024.117712_bib17","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1038\/s41467-022-35700-9","article-title":"Endogenous IL-1 receptor antagonist restricts healthy and malignant myeloproliferation","volume":"14","author":"Villatoro","year":"2023","journal-title":"Nat. Commun."},{"issue":"2","key":"10.1016\/j.biopha.2024.117712_bib18","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1038\/s41375-022-01767-y","article-title":"Biological drivers of clinical phenotype in myelofibrosis","volume":"37","author":"Mascarenhas","year":"2023","journal-title":"Leukemia"},{"issue":"20","key":"10.1016\/j.biopha.2024.117712_bib19","first-page":"2508","article-title":"CXCL8\/CXCR2 signaling mediates bone marrow fibrosis and represents a therapeutic target in myelofibrosis","volume":"141","author":"Dunbar","year":"2023","journal-title":"Blood"},{"issue":"24","key":"10.1016\/j.biopha.2024.117712_bib20","doi-asserted-by":"crossref","first-page":"5831","DOI":"10.3390\/jcm10245831","article-title":"Extramedullary Hematopoiesis of the Liver and Spleen","volume":"10","author":"Cenariu","year":"2021","journal-title":"J. Clin. Med"},{"issue":"5","key":"10.1016\/j.biopha.2024.117712_bib21","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1038\/nri.2017.142","article-title":"NF-\u03baB, inflammation, immunity and cancer: coming of age","volume":"18","author":"Taniguchi","year":"2018","journal-title":"Nat. Rev. Immunol."},{"issue":"6","key":"10.1016\/j.biopha.2024.117712_bib22","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1038\/s41575-020-0273-0","article-title":"JAK\u2013STAT pathway targeting for the treatment of inflammatory bowel disease","volume":"17","author":"Salas","year":"2020","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"issue":"7","key":"10.1016\/j.biopha.2024.117712_bib23","doi-asserted-by":"crossref","first-page":"2285","DOI":"10.1096\/fj.07-101816","article-title":"Interleukin-1 receptor-associated kinase (IRAK) -1-mediated NF-kappaB activation requires cytosolic and nuclear activity","volume":"22","author":"Liu","year":"2008","journal-title":"FASEB J."},{"issue":"1","key":"10.1016\/j.biopha.2024.117712_bib24","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.cytogfr.2009.11.005","article-title":"Dangerous liaisons: STAT3 and NF-\u03baB collaboration and crosstalk in cancer","volume":"21","author":"Grivennikov","year":"2010","journal-title":"Cytokine Growth Factor Rev."},{"issue":"70","key":"10.1016\/j.biopha.2024.117712_bib25","doi-asserted-by":"crossref","first-page":"33416","DOI":"10.18632\/oncotarget.26058","article-title":"Inhibition of interleukin-1 receptor-associated kinase 1 (IRAK1) as a therapeutic strategy","volume":"9","author":"Singer","year":"2018","journal-title":"Oncotarget"},{"issue":"9","key":"10.1016\/j.biopha.2024.117712_bib26","doi-asserted-by":"crossref","first-page":"1962","DOI":"10.1038\/leu.2016.377","article-title":"Mass cytometry analysis reveals hyperactive NF Kappa B signaling in myelofibrosis and secondary acute myeloid leukemia","volume":"31","author":"Fisher","year":"2017","journal-title":"Leukemia"},{"issue":"6","key":"10.1016\/j.biopha.2024.117712_bib27","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1002\/JLB.3MIR0817-346RRR","article-title":"Modulating inflammation through the negative regulation of NF-\u03baB signaling","volume":"103","author":"Rothschild","year":"2018","journal-title":"J. Leukoc. Biol."},{"issue":"22","key":"10.1016\/j.biopha.2024.117712_bib28","doi-asserted-by":"crossref","first-page":"9184","DOI":"10.1073\/pnas.1105398108","article-title":"NF-\u03baB dysregulation in microRNA-146a\u2013deficient mice drives the development of myeloid malignancies","volume":"108","author":"Zhao","year":"2011","journal-title":"Proc. Natl. Acad. Sci."},{"issue":"6","key":"10.1016\/j.biopha.2024.117712_bib29","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1084\/jem.20101823","article-title":"miR-146a is a significant brake on autoimmunity, myeloproliferation, and cancer in mice","volume":"208","author":"Boldin","year":"2011","journal-title":"J. Exp. Med."},{"issue":"34","key":"10.1016\/j.biopha.2024.117712_bib30","doi-asserted-by":"crossref","first-page":"E7140","DOI":"10.1073\/pnas.1706833114","article-title":"miR-146a \u2013 Traf6 regulatory axis controls autoimmunity and myelopoiesis, but is dispensable for hematopoietic stem cell homeostasis and tumor suppression","volume":"114","author":"Magilnick","year":"2017","journal-title":"Proc. Natl. Acad. Sci."},{"issue":"10","key":"10.1016\/j.biopha.2024.117712_bib31","doi-asserted-by":"crossref","first-page":"2648","DOI":"10.1038\/s41375-020-0767-3","article-title":"miR-146a rs2431697 identifies myeloproliferative neoplasm patients with higher secondary myelofibrosis progression risk","volume":"34","author":"Ferrer-Mar\u00edn","year":"2020","journal-title":"Leukemia"},{"issue":"9","key":"10.1016\/j.biopha.2024.117712_bib32","doi-asserted-by":"crossref","first-page":"2381","DOI":"10.3390\/cancers12092381","article-title":"Murine models of myelofibrosis","volume":"12","author":"Jacquelin","year":"2020","journal-title":"Cancers (Basel)"},{"issue":"3","key":"10.1016\/j.biopha.2024.117712_bib33","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1158\/2159-8290.CD-15-0095","article-title":"Aberrant cytokine production by nonmalignant cells in the pathogenesis of myeloproliferative tumors and response to JAK inhibitor therapies","volume":"5","author":"Belver","year":"2015","journal-title":"Cancer Discov."},{"issue":"11","key":"10.1016\/j.biopha.2024.117712_bib34","doi-asserted-by":"crossref","first-page":"3585","DOI":"10.31557\/APJCP.2021.22.11.3585","article-title":"Predictive Value of miR-146a rs2431697 Polymorphism to Myelofibrosis Progression in Patients with Myeloproliferative Neoplasm","volume":"22","author":"Aref","year":"2021","journal-title":"Asian Pac. J. Cancer Prev."},{"issue":"5","key":"10.1016\/j.biopha.2024.117712_bib35","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1097\/MOH.0000000000000669","article-title":"Still a burning question: the interplay between inflammation and fibrosis in myeloproliferative neoplasms","volume":"28","author":"Gleitz","year":"2021","journal-title":"Curr. Opin. Hematol."},{"issue":"7","key":"10.1016\/j.biopha.2024.117712_bib36","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.3324\/haematol.2021.279415","article-title":"Retrospective analysis of pacritinib in patients with myelofibrosis and severe thrombocytopenia","volume":"107","author":"Verstovsek","year":"2022","journal-title":"Haematologica"},{"issue":"8","key":"10.1016\/j.biopha.2024.117712_bib37","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1080\/17474086.2022.2112565","article-title":"Pacritinib for the treatment of patients with myelofibrosis and thrombocytopenia","volume":"15","author":"Mascarenhas","year":"2022","journal-title":"Expert Rev. Hematol."},{"issue":"2","key":"10.1016\/j.biopha.2024.117712_bib38","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1007\/BF01600283","article-title":"Megakaryocytopoiesis in haematological disorders: Diagnostic features of bone marrow biopsies","volume":"418","author":"Thiele","year":"1991","journal-title":"Virchows Arch. A Pathol. Anat. Histopathol."},{"issue":"12","key":"10.1016\/j.biopha.2024.117712_bib39","doi-asserted-by":"crossref","first-page":"1550","DOI":"10.1038\/modpathol.3800480","article-title":"Morphologic and immunohistochemical evaluation of splenic hematopoietic proliferations in neoplastic and benign disorders","volume":"18","author":"O\u2019Malley","year":"2005","journal-title":"Mod. Pathol."},{"key":"10.1016\/j.biopha.2024.117712_bib40","series-title":"Blood and Bone Marrow Pathology","first-page":"45","article-title":"Normal bone marrow histology","author":"Moonim","year":"2011"},{"issue":"8","key":"10.1016\/j.biopha.2024.117712_bib41","first-page":"1128","article-title":"European consensus on grading bone marrow fibrosis and assessment of cellularity","volume":"90","author":"Thiele","year":"2005","journal-title":"Haematologica"},{"issue":"6","key":"10.1016\/j.biopha.2024.117712_bib42","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1111\/his.12871","article-title":"Problems and pitfalls in grading of bone marrow fibrosis, collagen deposition and osteosclerosis \u2013 a consensus-based study","volume":"68","author":"Kvasnicka","year":"2016","journal-title":"Histopathology"},{"issue":"7","key":"10.1016\/j.biopha.2024.117712_bib43","doi-asserted-by":"crossref","first-page":"1326","DOI":"10.1002\/ajh.27322","article-title":"miR-146a \u2212\/\u2212 mice model reveals that NF-\u03baB inhibition reverts inflammation-driven myelofibrosis-like phenotype","volume":"99","author":"Cuenca-Zamora","year":"2024","journal-title":"Am. J. Hematol."},{"issue":"1","key":"10.1016\/j.biopha.2024.117712_bib44","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1038\/s41467-017-00972-z","article-title":"An NF-\u03baB-microRNA regulatory network tunes macrophage inflammatory responses","volume":"8","author":"Mann","year":"2017","journal-title":"Nat. Commun."},{"issue":"11","key":"10.1016\/j.biopha.2024.117712_bib45","doi-asserted-by":"crossref","first-page":"1681","DOI":"10.1002\/cncr.34707","article-title":"Early intervention in myelofibrosis and impact on outcomes: A pooled analysis of the COMFORT-I and COMFORT-II studies","volume":"129","author":"Verstovsek","year":"2023","journal-title":"Cancer"},{"issue":"5","key":"10.1016\/j.biopha.2024.117712_bib46","doi-asserted-by":"crossref","first-page":"e225","DOI":"10.1016\/S2352-3026(17)30027-3","article-title":"Pacritinib versus best available therapy for the treatment of myelofibrosis irrespective of baseline cytopenias (PERSIST-1): an international, randomised, phase 3 trial","volume":"4","author":"Mesa","year":"2017","journal-title":"Lancet Haematol."},{"issue":"19","key":"10.1016\/j.biopha.2024.117712_bib47","doi-asserted-by":"crossref","first-page":"5835","DOI":"10.1182\/bloodadvances.2023010151","article-title":"Pacritinib is a potent ACVR1 inhibitor with significant anemia benefit in patients with myelofibrosis","volume":"7","author":"Oh","year":"2023","journal-title":"Blood Adv."},{"issue":"5","key":"10.1016\/j.biopha.2024.117712_bib48","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1001\/jamaoncol.2017.5818","article-title":"Pacritinib vs Best Available Therapy, Including Ruxolitinib, in Patients With Myelofibrosis: A Randomized Clinical Trial","volume":"4","author":"Mascarenhas","year":"2018","journal-title":"JAMA Oncol."},{"issue":"7","key":"10.1016\/j.biopha.2024.117712_bib49","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1007\/s40265-022-01718-y","article-title":"Pacritinib: First Approval","volume":"82","author":"Lamb","year":"2022","journal-title":"Drugs"},{"issue":"1","key":"10.1016\/j.biopha.2024.117712_bib50","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.ccr.2013.05.006","article-title":"Targeting IRAK1 as a therapeutic approach for myelodysplastic syndrome","volume":"24","author":"Rhyasen","year":"2013","journal-title":"Cancer Cell"},{"issue":"11","key":"10.1016\/j.biopha.2024.117712_bib51","doi-asserted-by":"crossref","first-page":"1751","DOI":"10.1038\/leu.2011.148","article-title":"SB1518, a novel macrocyclic pyrimidine-based JAK2 inhibitor for the treatment of myeloid and lymphoid malignancies","volume":"25","author":"Hart","year":"2011","journal-title":"Leukemia"},{"issue":"9","key":"10.1016\/j.biopha.2024.117712_bib52","doi-asserted-by":"crossref","DOI":"10.3390\/cancers12092446","article-title":"Anti-Glucosylsphingosine Autoimmunity, JAK2V617F-Dependent Interleukin-1\u03b2 and JAK2V617F-Independent Cytokines in Myeloproliferative Neoplasms","volume":"12","author":"Allain-Maillet","year":"2020","journal-title":"Cancers (Basel)"},{"issue":"1","key":"10.1016\/j.biopha.2024.117712_bib53","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1189\/jlb.72.1.9","article-title":"Role of CXCL1 in tumorigenesis of melanoma","volume":"72","author":"Dhawan","year":"2002","journal-title":"J. Leukoc. Biol."},{"issue":"8","key":"10.1016\/j.biopha.2024.117712_bib54","doi-asserted-by":"crossref","first-page":"2427","DOI":"10.3390\/ijms19082427","article-title":"Interaction between Tumor-Associated Dendritic Cells and Colon Cancer Cells Contributes to Tumor Progression via CXCL1","volume":"19","author":"Hsu","year":"2018","journal-title":"Int J. Mol. Sci."},{"issue":"2","key":"10.1016\/j.biopha.2024.117712_bib55","first-page":"1036","article-title":"Complementary action of CXCL1 and CXCL8 in pathogenesis of gastric carcinoma","volume":"11","author":"Chen","year":"2018","journal-title":"Int J. Clin. Exp. Pathol."},{"key":"10.1016\/j.biopha.2024.117712_bib56","article-title":"A Review of CXCL1 in Cardiac Fibrosis","volume":"8","author":"Wu","year":"2021","journal-title":"Front Cardiovasc Med"},{"issue":"2","key":"10.1016\/j.biopha.2024.117712_bib57","doi-asserted-by":"crossref","first-page":"234","DOI":"10.3390\/biom12020234","article-title":"Resident self-tissue of proinflammatory cytokines rather than their systemic levels correlates with development of myelofibrosis in Gata1low mice","volume":"12","author":"Zingariello","year":"2022","journal-title":"Biomolecules"},{"issue":"2","key":"10.1016\/j.biopha.2024.117712_bib58","first-page":"2060","article-title":"CXCL8 and its cognate receptors CXCR1\/CXCR2 in primary myelofibrosis","volume":"109","author":"Vermeersch","year":"2024","journal-title":"Haematologica"},{"issue":"10","key":"10.1016\/j.biopha.2024.117712_bib59","doi-asserted-by":"crossref","first-page":"1356","DOI":"10.1200\/JCO.2010.32.9490","article-title":"Circulating interleukin (IL)-8, IL-2R, IL-12, and IL-15 levels are independently prognostic in primary myelofibrosis: a comprehensive cytokine profiling study","volume":"29","author":"Tefferi","year":"2011","journal-title":"J. Clin. Oncol."},{"issue":"ement 1","key":"10.1016\/j.biopha.2024.117712_bib60","article-title":"TNF\u03b1 Controls the Delicate Balance between Erythropoiesis and Stem Cell Exhaustion during Inflammatory Stress","volume":"138","author":"Guerra","year":"2021","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.biopha.2024.117712_bib61","doi-asserted-by":"crossref","first-page":"1978","DOI":"10.1038\/s41375-019-0379-y","article-title":"Cytokine production in myelofibrosis exhibits differential responsiveness to JAK-STAT, MAP kinase, and NF\u03baB signaling","volume":"33","author":"Fisher","year":"2019","journal-title":"Leukemia"},{"issue":"8","key":"10.1016\/j.biopha.2024.117712_bib62","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1016\/j.exphem.2005.05.002","article-title":"Human mesenchymal stem cells require monocyte-mediated activation to suppress alloreactive T cells","volume":"33","author":"Groh","year":"2005","journal-title":"Exp. Hematol."},{"issue":"11","key":"10.1016\/j.biopha.2024.117712_bib63","doi-asserted-by":"crossref","first-page":"3888","DOI":"10.1172\/JCI64397","article-title":"Spleens of myelofibrosis patients contain malignant hematopoietic stem cells","volume":"122","author":"Wang","year":"2012","journal-title":"J. Clin. Invest"},{"issue":"23","key":"10.1016\/j.biopha.2024.117712_bib64","doi-asserted-by":"crossref","first-page":"3387","DOI":"10.1182\/blood.2021013450","article-title":"Unique molecular and functional features of extramedullary hematopoietic stem and progenitor cell reservoirs in humans","volume":"139","author":"Mende","year":"2022","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.biopha.2024.117712_bib65","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1186\/s12967-023-04393-z","article-title":"Fibrosis and bone marrow: understanding causation and pathobiology","volume":"21","author":"Ghosh","year":"2023","journal-title":"J. Transl. Med"},{"key":"10.1016\/j.biopha.2024.117712_bib66","doi-asserted-by":"crossref","DOI":"10.12703\/r\/12-23","article-title":"Recent advances in therapies for primary myelofibrosis","volume":"12","author":"Vainchenker","year":"2023","journal-title":"Fac. Rev."},{"issue":"11","key":"10.1016\/j.biopha.2024.117712_bib67","doi-asserted-by":"crossref","DOI":"10.1172\/JCI154092","article-title":"TGF-\u03b2 signaling in myeloproliferative neoplasms contributes to myelofibrosis without disrupting the hematopoietic niche","volume":"132","author":"Yao","year":"2022","journal-title":"J. Clin. Investig."},{"issue":"20","key":"10.1016\/j.biopha.2024.117712_bib68","doi-asserted-by":"crossref","DOI":"10.1111\/jcmm.70138","article-title":"<scp>JAK2V617F<\/scp> -dependent down regulation of <scp>SHP<\/scp> -1 expression participates in the selection of myeloproliferative neoplasm cells in the presence of <scp>TGF<\/scp> -\u03b2","volume":"28","author":"Aoun","year":"2024","journal-title":"J. Cell Mol. Med"},{"issue":"11","key":"10.1016\/j.biopha.2024.117712_bib69","doi-asserted-by":"crossref","first-page":"3008","DOI":"10.1158\/1078-0432.CCR-11-3145","article-title":"Ruxolitinib: The First FDA Approved Therapy for the Treatment of Myelofibrosis","volume":"18","author":"Mascarenhas","year":"2012","journal-title":"Clin. Cancer Res."},{"issue":"1","key":"10.1016\/j.biopha.2024.117712_bib70","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1002\/jha2.854","article-title":"Changes in bone marrow fibrosis during momelotinib or ruxolitinib therapy do not correlate with efficacy outcomes in patients with myelofibrosis","volume":"5","author":"Oh","year":"2024","journal-title":"EJHaem"},{"issue":"ement 1","key":"10.1016\/j.biopha.2024.117712_bib71","article-title":"Retrospective Analysis of the Relationship between Transfusion Independence and Bone Marrow Fibrosis Reduction in Patients with Myelofibrosis Treated with Pacritinib Versus Ruxolitinib","volume":"142","author":"Oh","year":"2023","journal-title":"Blood"},{"issue":"ement 1","key":"10.1016\/j.biopha.2024.117712_bib72","article-title":"Platelet Response in Pacritinib-Treated Patients with Cytopenic Myelofibrosis: A Retrospective Analysis of PERSIST-2 and PAC203 Studies","volume":"142","author":"Vachhani","year":"2023","journal-title":"Blood"},{"issue":"ement 1","key":"10.1016\/j.biopha.2024.117712_bib73","article-title":"Pelabresib in Combination with Ruxolitinib for Janus Kinase Inhibitor Treatment-Na\u00efve Patients with Myelofibrosis: Results of the MANIFEST-2 Randomized, Double-Blind, Phase 3 Study","volume":"142","author":"Rampal","year":"2023","journal-title":"Blood"},{"issue":"32","key":"10.1016\/j.biopha.2024.117712_bib74","doi-asserted-by":"crossref","first-page":"4993","DOI":"10.1200\/JCO.22.01972","article-title":"MANIFEST: Pelabresib in Combination With Ruxolitinib for Janus Kinase Inhibitor Treatment-Na\u00efve Myelofibrosis","volume":"41","author":"Mascarenhas","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.biopha.2024.117712_bib75","doi-asserted-by":"crossref","DOI":"10.1182\/blood.2023022804","article-title":"In vivo ablation of NF\u03baB cascade effectors alleviates disease burden in myeloproliferative neoplasms","author":"Laranjeira","year":"2024","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.biopha.2024.117712_bib76","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1038\/s41584-021-00726-8","article-title":"Janus kinase-targeting therapies in rheumatology: a mechanisms-based approach","volume":"18","author":"Tanaka","year":"2022","journal-title":"Nat. Rev. Rheuma"},{"issue":"5","key":"10.1016\/j.biopha.2024.117712_bib77","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1007\/s12185-022-03299-8","article-title":"Novel treatments for myelofibrosis: beyond JAK inhibitors","volume":"115","author":"Tremblay","year":"2022","journal-title":"Int J. Hematol."},{"issue":"4","key":"10.1016\/j.biopha.2024.117712_bib78","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1002\/hep.32746","article-title":"Janus kinase 2 inhibition by pacritinib as potential therapeutic target for liver fibrosis","volume":"77","author":"Torres","year":"2023","journal-title":"Hepatology"},{"issue":"4","key":"10.1016\/j.biopha.2024.117712_bib79","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1158\/2643-3230.BCD-22-0176","article-title":"The role of inflammation in the initiation and progression of myeloid neoplasms","volume":"4","author":"Balandr\u00e1n","year":"2023","journal-title":"Blood Cancer Discov."},{"issue":"1","key":"10.1016\/j.biopha.2024.117712_bib80","doi-asserted-by":"crossref","first-page":"5346","DOI":"10.1038\/s41467-022-32927-4","article-title":"Inhibition of interleukin-1\u03b2 reduces myelofibrosis and osteosclerosis in mice with JAK2-V617F driven myeloproliferative neoplasm","volume":"13","author":"Rai","year":"2022","journal-title":"Nat. Commun."}],"container-title":["Biomedicine &amp; Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332224015981?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332224015981?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T13:15:51Z","timestamp":1787922951000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0753332224015981"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12]]},"references-count":80,"alternative-id":["S0753332224015981"],"URL":"https:\/\/doi.org\/10.1016\/j.biopha.2024.117712","relation":{},"ISSN":["0753-3322"],"issn-type":[{"value":"0753-3322","type":"print"}],"subject":[],"published":{"date-parts":[[2024,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pacritinib prevents inflammation-driven myelofibrosis-like phenotype in a miR-146a-\/- murine model","name":"articletitle","label":"Article Title"},{"value":"Biomedicine & Pharmacotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.biopha.2024.117712","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Author(s). Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"117712"}}